Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
Abstract Background Sodium zirconium cyclosilicate (SZC) has recently emerged as a therapeutic option for the management of acute hyperkalemia. Nevertheless, the relative effectiveness, safety, and financial considerations of SZC therapy versus conventional hemodialysis therapy remain uncertain. Met...
Main Authors: | Hayato Fujioka, Teruhiko Imamura, Tsutomu Koike, Shingo Yokoyama, Kota Kakeshita, Hidenori Yamazaki, Koichiro Kinugawa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Renal Replacement Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41100-023-00512-0 |
Similar Items
-
Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
by: Teruhiko Imamura, et al.
Published: (2022-12-01) -
Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
by: Teruhiko Imamura, et al.
Published: (2022-11-01) -
Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
by: Teruhiko Imamura, et al.
Published: (2021-11-01) -
Constipation as a Drug-Related Adverse Effect in Patients with Hyperkalemia: Sodium Zirconium Cyclosilicate versus Conventional Potassium Binders
by: Yuki Hida, et al.
Published: (2023-09-01) -
Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
by: Teruhiko Imamura, et al.
Published: (2022-09-01)